Clinical Trial

The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery

Study acronym: TheRAPy
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 4, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
The TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a policy of crystalloid priming reduces RBC transfusion for patients undergoing cardiac surgery on cardiopulmonary bypass. It will also provide information about key parameters of the TheRAPy full-scale trial.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-01-18; most recent amendment 2025-02-27.
Status change: Not Yet Recruiting → Recruiting 2025-02-27
Trial Details
NCT Number NCT06230198
Lead Sponsor Population Health Research Institute
Conditions Red Blood Cell Transfusion
Enrollment 4,500 participants
Start Date 2024-12-04
Primary Completion 2026-01 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-03-04